Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Radiation Oncologists

Articles with lock require a subscription to GLG News | Request a free trial
September 30, 2008
Faster radiation delivery is as good as conventional radiation treatment.
Analysis of: Quicker Therapy Just as Good for Breast Cancer | www.newser.com
Author: GLG Expert Contributor
A 12 year follow up study in Canada recently proved that local control and toxicity was equivalent in 3 weeks of radiation (hypofractionated) verses 5-7 weeks of radiation. 
September 29, 2008
3 weeks IS as good!
Analysis of: Shorter Radiation for Cancer of the Breast | www.nytimes.com
Author: GLG Expert Contributor
As a memebr of the START Trial group I can confirm that over the period of this study follow up (5 years) in many thousands of patients the recurrence rate following lumpectomy for early breast cancer and only 3 weeks of radiotherapy was the same as that for 5 weeks and very low (approx 3-4%). The 3...
September 25, 2008
Tomotherapy, Protons, Short Course Breast RT - ASTRO 2008
Analysis of: Hospitals Look to Nuclear Tool to Fight Cancer | www.nytimes.com
Author: GLG Expert Contributor
Tomotherapy may do well after all with newer bells and whistles introduced at ASTRO 2008. Protons are likely to die leaving investors with a huge bill and dwindling ROI. Short course breast radiotherapy is not worth the risk.
September 17, 2008
Proton Radiotherapy: A Review
Analysis of: Proton Radiotherapy: A Review | www.nytimes.com
Author: GLG Expert Contributor
Proton Radiotherapy is rapidly becoming a growing market in the radiation oncology world. 
July 14, 2008
Costly cancer drugs have to be cost-effective
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
This article is important because: 1) Costly cancer drugs are unsustainable in our healthcare system 2) Indiscriminate use of Avastin swallows up money that would be better spent elsewhere
May 27, 2008
You get what you pay for
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: GLG Expert Contributor
A single payer, national system does work, but may not necessarily be in the best interest of all parties.   Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.
Charles BennettApril 4, 2008
Advantages of SenoRx Contura over Mammosite Breast Brachytherapy system.
Analysis of: A new player in the growing Breast Brachytherapy field | www.senorx.com
Author: Charles Bennett, Radiation Oncologist , Robert Boissoneault Oncology Institute
SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System.  These advantages include: 1.  Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...
February 28, 2008
Roche Herceptin targeted cancer drugs
Analysis of: Cancer drugs should be tailored to fit patient | www.fiercebioresearcher.com
Author: GLG Expert Contributor
Essentially we are moving into an arena where cancer drugs will be more and more specific to individual groups of patients with cancer. For example in breast cancer all patients used to be treated the same. Now patients with tumours that are ER positive are given hormonal therapies and not those with...
November 16, 2007
Watch out Tomo....here comes some competition
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: GLG Expert Contributor
Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.    
November 16, 2007
This trial confirms zevalin's effectiveness - limited prescribing remains a block to timely use.
Analysis of: Major Phase 3 Trial Shows Zevalin(R) Extends Progression-Free Survival in one of the most common types of Lymphoma | www.pipelinereview.com
Author: GLG Expert Contributor
Zevalin represents the first of an exciting new class of drugs which in many ways can be thought of as a chemotheurapeutic agent though the cell death mechanism is ionizing radiation. With a high response rate (82%) and a low toxicity -reversable hematologic effect only, it has the potential to be a...

Page : 1 2 3 4 5 6 7 8 Next1 to 10 of 76

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637